Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $32.00

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $32.00.

A number of equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Finally, Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $31.49 on Thursday. Catalyst Pharmaceuticals has a 1 year low of $19.05 and a 1 year high of $32.56. The firm has a 50-day moving average of $31.41 and a 200 day moving average of $27.70. The stock has a market cap of $3.86 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Parkside Financial Bank & Trust lifted its position in shares of Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 469 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in shares of Catalyst Pharmaceuticals by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 472 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 4.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 474 shares during the last quarter. Lifestyle Asset Management Inc. increased its stake in Catalyst Pharmaceuticals by 3.4% in the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock worth $393,000 after buying an additional 553 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares in the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).